These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 23933386)

  • 1. Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification.
    Chen CC; Chu CB; Liu KJ; Huang CY; Chang JY; Pan WY; Chen HH; Cheng YH; Lee KD; Chen MF; Kuo CC; Chen LT
    Biochem Pharmacol; 2013 Oct; 86(7):872-87. PubMed ID: 23933386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil.
    Chen CC; Chen LT; Tsou TC; Pan WY; Kuo CC; Liu JF; Yeh SC; Tsai FY; Hsieh HP; Chang JY
    Br J Cancer; 2007 Aug; 97(3):334-44. PubMed ID: 17609664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway.
    Gao AM; Ke ZP; Shi F; Sun GC; Chen H
    Chem Biol Interact; 2013 Oct; 206(1):100-8. PubMed ID: 23994249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
    Chian S; Li YY; Wang XJ; Tang XW
    Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway.
    Shim GS; Manandhar S; Shin DH; Kim TH; Kwak MK
    Free Radic Biol Med; 2009 Dec; 47(11):1619-31. PubMed ID: 19751820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
    Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
    Shiiba M; Yamagami H; Yamamoto A; Minakawa Y; Okamoto A; Kasamatsu A; Sakamoto Y; Uzawa K; Takiguchi Y; Tanzawa H
    Oncol Rep; 2017 Apr; 37(4):2025-2032. PubMed ID: 28259989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs.
    Wang XJ; Li Y; Luo L; Wang H; Chi Z; Xin A; Li X; Wu J; Tang X
    Free Radic Biol Med; 2014 May; 70():68-77. PubMed ID: 24556415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs.
    Tang X; Wang H; Fan L; Wu X; Xin A; Ren H; Wang XJ
    Free Radic Biol Med; 2011 Jun; 50(11):1599-609. PubMed ID: 21402146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldo-keto reductase 1C subfamily genes in skin are UV-inducible: possible role in keratinocytes survival.
    Marín YE; Seiberg M; Lin CB
    Exp Dermatol; 2009 Jul; 18(7):611-8. PubMed ID: 19320734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds.
    MacLeod AK; McMahon M; Plummer SM; Higgins LG; Penning TM; Igarashi K; Hayes JD
    Carcinogenesis; 2009 Sep; 30(9):1571-80. PubMed ID: 19608619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced B-Raf-mediated NRF2 gene transcription and HATs-mediated NRF2 protein acetylation contributes to ABCC1-mediated chemoresistance and glutathione-mediated survival in acquired topoisomerase II poison-resistant cancer cells.
    Chen HH; Chang HH; Chang JY; Tang YC; Cheng YC; Lin LM; Cheng SY; Huang CH; Sun MW; Chen CT; Kuo CC
    Free Radic Biol Med; 2017 Dec; 113():505-518. PubMed ID: 29080842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes.
    McMahon M; Itoh K; Yamamoto M; Chanas SA; Henderson CJ; McLellan LI; Wolf CR; Cavin C; Hayes JD
    Cancer Res; 2001 Apr; 61(8):3299-307. PubMed ID: 11309284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3',4',5',5,7-pentamethoxyflavone sensitizes Cisplatin-resistant A549 cells to Cisplatin by inhibition of Nrf2 pathway.
    Hou X; Bai X; Gou X; Zeng H; Xia C; Zhuang W; Chen X; Zhao Z; Huang M; Jin J
    Mol Cells; 2015 May; 38(5):396-401. PubMed ID: 25843086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up-down regulation of HO-1 and iNOS gene expressions by ethyl pyruvate via recruiting p300 to Nrf2 and depriving It from p65.
    Kim SW; Lee HK; Shin JH; Lee JK
    Free Radic Biol Med; 2013 Dec; 65():468-476. PubMed ID: 23891677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers.
    Matsunaga T; Hojo A; Yamane Y; Endo S; El-Kabbani O; Hara A
    Chem Biol Interact; 2013 Feb; 202(1-3):234-42. PubMed ID: 23165153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents.
    Wang XJ; Hayes JD; Wolf CR
    Cancer Res; 2006 Nov; 66(22):10983-94. PubMed ID: 17108137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptomic Profiling Reveals AKR1C1 and AKR1C3 Mediate Cisplatin Resistance in Signet Ring Cell Gastric Carcinoma via Autophagic Cell Death.
    Phoo NLL; Dejkriengkraikul P; Khaw-On P; Yodkeeree S
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.